» Articles » PMID: 29132677

Adjuvant Therapies in Food Immunotherapy

Overview
Date 2017 Nov 15
PMID 29132677
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Finding an effective curative treatment for food allergy is a research priority. Although oral immunotherapy (OIT) is effective at inducing desensitization, the temporary nature of this effect and high rates of adverse reactions have highlighted a need for novel strategies to improve tolerance induction and safety. One such strategy is the use of an adjuvant together with food immunotherapy to either suppress allergic reactions and/or modulate the underlying allergic immune response. In particular, the use of bacterial adjuvants seems to be a promising means of enhancing OIT-induced sustained unresponsiveness and warrants further investigation.

Citing Articles

LZZAY01 accelerated autophagy and apoptosis in colon cancer cells and improved gut microbiota in CAC mice.

Yang W, Li T, An S, Chen R, Zhao Y, Cui J Microbiol Spectr. 2025; 13(2):e0186124.

PMID: 39792005 PMC: 11792455. DOI: 10.1128/spectrum.01861-24.


Maternal gestational TMC3115 treatment shapes construction of offspring gut microbiota and development of immune system and induces immune tolerance to food allergen.

Cheng R, Zhang Y, Yang Y, Ren L, Li J, Wang Y Front Cell Infect Microbiol. 2022; 12:1045109.

PMID: 36452299 PMC: 9701730. DOI: 10.3389/fcimb.2022.1045109.


Oral Immunotherapy for Food-Allergic Children: A Pro-Con Debate.

Mori F, Giovannini M, Barni S, Jimenez-Saiz R, Munblit D, Biagioni B Front Immunol. 2021; 12:636612.

PMID: 34650547 PMC: 8507468. DOI: 10.3389/fimmu.2021.636612.


Study protocol of a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy....

Loke P, Lozinsky A, Orsini F, Wong L, Leung A, Tham E BMJ Open. 2021; 11(7):e044331.

PMID: 34233966 PMC: 8264865. DOI: 10.1136/bmjopen-2020-044331.


Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy.

Langlois A, Lavergne M, Leroux H, Killer K, Azzano P, Paradis L Allergy Asthma Clin Immunol. 2020; 16:25.

PMID: 32328115 PMC: 7165401. DOI: 10.1186/s13223-020-00419-z.